Search results
Found 22 matches for
Lapidaire Group: Brain Health Vascular Imaging
Our group aims to make early diagnosis and continuous check-ups for (vascular) diseases accurate, affordable, and accessible for everyone. We focus on women’s vascular health and global health and aim to better understand the impact of hypertensive disorders of pregnancy on the brain.
Valkovič Group: Body MRS Group
Pushing the Limits of Multi-nuclear Magnetic Resonance Spectroscopy of the Heart, Liver and Muscle
Zhang Group: Artificial Intelligence in Cardiovascular Imaging
We work with clinicians and MR scientists on a day-to-day basis to develop novel AI machine-learning approaches for cardiovascular imaging.
Akbar Group: Extracellular Vesicles in Cardiovascular, Inflammatory and Metabolic Disease
The Akbar Lab is interested in defining the therapeutic and diagnostic potential of extracellular vesicles for immunomodulation and precision medicine in cardiovascular, metabolic, and inflammatory diseases.
Tyler Group
Development and Application of Cardiac Magnetic Resonance Imaging and Spectroscopy
Pavlides Group: Quantitative MR and liver disease
Our group investigates how MR techniques can be used to improve the care of patients with liver disease. The scope of our work is broad and ranges from evaluation of mature MR techniques in large multicentre studies, to proof-of-concept studies using new methods, or new clinical applications of existing technologies.
Neubauer Group: Oxford Centre for Clinical Magnetic Resonance Research
OCMR uses sophisticated cardiac MR imaging and spectroscopy methods to phenotype cardiovascular disease – in small-scale proof-of-principle studies, large-scale multicentre clinical trials and ultra-large scale population imaging programmes. As well as running their own research programmes, OCMR serves as a collaboration partner to any group wanting to strengthen their clinical research with state of the art non-invasive phenotyping tools.
Redwood Group: Cardiac Contractility
Defining important functional paradigms that lead to inherited cardiomyopathies, in search of novel treatments.
Ferreira Group: Quantitative cardiac magnetic resonance myocardial tissue characterisation
We have expertise in the study of heart disease using cardiovascular magnetic resonance (CMR), particularly quantitative techniques such as myocardial T1-mapping.
Betts Group: Cardiac Rhythm Management
The CRM group’s principal research interests are the treatment of abnormal heart rhythms and the resynchronisation of abnormal electrical conduction in heart failure patients. There is a particular focus on the use of novel and emerging technologies.
Channon Group: Cardiovascular functional genomics and redox signalling
We work to understand how early changes in cells of the cardiovascular system, such as endothelial cells and leukocytes, are related to cardiovascular disease, with a particular focus on redox biology.
Watkins Group: Inherited Heart Muscle Disease Group
Using human genetics and functional genomics to understand inherited heart disease
Inherited Heart Disease Service
We make about 1600 patient contacts a year with those who have, or are at risk of having, an Inherited Cardiac Condition (eg cardiomyopathies and inherited arrhythmias) across all age ranges. We provide cardiology screening (ECG, Echocardiography) and clinical genetics during an initial single clinic visit, and provide telephone and e-mail support throughout the working week. We have made internationally recognised contributions in this area, in particular the use of cardiac MRI in diagnosis, and understanding of the underlying genetic basis of Inherited Cardiac Conditions.
Leeson Group: Preventive Cardiology Research Group
Our aim is to develop better ways to identify early disease and improve cardiovascular health for young people. This is achieved by undertaking work in three areas: (1) Identification of novel markers of early disease to better understand how disease becomes established (2) Performing cardiovascular prevention trials in young adults to understand how to modify early disease and improve health (3) Application of artificial intelligence to imaging and research datasets to identify next generation imaging and management approaches.
Banning Group
Use of minimally invasive techniques to improve heart function.
Bhattacharya Group: Developing novel therapeutics for inflammatory diseases
Our goals are to develop therapeutics targeting the chemokine network in inflammatory diseases affecting the heart, blood vessels and other organ systems.
Choudhury Group: Understanding Inflammatory processes in Atherosclerosis and Acute Myocardial Infarction
- Acute Multidisciplinary Imaging and Interventional Centre
- Division of Cardiovascular Medicine
- Metabolism in Molecular Medicine
This translational science laboratory aims to understand the functionally important heterogeneity in human cardiovascular disease to allow stratification of pathology and enable targeted therapies.
Myerson Group: Heart Valve Disease
We investigate diseases of the heart valves – how widespread the problem is, what the causes are, who is at risk from future problems and what treatments can improve outcomes for patients.
Rider Group: Obesity, Heart Failure, Linking Myocardial Metabolism and Function
We use multi-parametric cardiac magnetic resonance imaging and multinuclear magnetic resonance spectroscopy to non-invasively investigate the relationship between cardiac metabolism and cardiac function.
Reilly Group: Atrial Fibrillation and Cardiac Fibrosis: from molecular signalling to drug discovery.
Our group aims to uncover the molecular mechanisms that drive cardiac fibrosis and the electrical remodelling underlying atrial fibrillation, one of the most common cardiac rhythm disorders. We are particularly interested in the functional cross-talk between cardiomyocytes and fibroblasts, as well as the roles of microRNA networks and calcitonin-receptor–dependent signalling pathways in the atrial myocardium. Our work integrates fundamental mechanistic discovery with translational approaches, including early-stage drug development.